Business Wire04.14.16
Autonomic Technologies Inc. (ATI) has appointed Niamh Pellegrini as president, CEO, and member of its board of directors. Pellegrini will lead the company’s efforts to bring innovative therapies to physicians and their patients who suffer from severe and disabling headaches.
Pellegrini has more than 25 years of experience in the healthcare industry, including a broad range of operational, strategic and commercial leadership positions. Most recently, Pellegrini was president of North America for Thoratec, a developer of implantable mechanical circulatory support therapies. Previously, she held senior sales, marketing, business development and general management positions across a number of business units of Johnson and Johnson, including Acclarent and LifeScan.
“It is an exciting time to join ATI as we expand our commercial presence in Europe and accelerate our U.S. clinical trial. The published clinical results for the Pulsante Microstimulator are compelling and demonstrate that we truly can improve the quality of life for many patients by freeing them from the pain of disabling headaches,” said Pellegrini.
Company executives also appointed Gerhard Burbach, former CEO of Thoratec and currently an independent board member of ATI, as been board chairman.
“Niamh brings an impressive track record of driving growth in multinational medical device businesses where she has consistently built and maintained leading market positions,” said Burbach. "We are pleased to have such an accomplished executive join ATI at this important point in the company’s development, and we look forward to strong commercial and clinical success under her very capable leadership."
Autonomic Technologies Inc. develops and commercializes therapies to treat autonomic disorders, particularly severe headaches. The company’s initial product, the Pulsante Microstimulator, is CE marked in Europe for the treatment of cluster headache. The device (also known as ATI Neurostimulation System) is under an investigational device exemption study in the United States for the treatment of chronic cluster headache. ATI is backed by European and U.S. investors including Edmond de Rothschild Investment Partners, Forbion Capital Partners, HBM Healthcare Investments, Kleiner Perkins Caufield and Byers, InterWest Partners, Aberdare Ventures, Novartis Venture Funds, Capital Royalty Group and Cleveland Clinic. The company is headquartered in the San Francisco Bay, Calif., area, with offices in Germany and Switzerland.
Pellegrini has more than 25 years of experience in the healthcare industry, including a broad range of operational, strategic and commercial leadership positions. Most recently, Pellegrini was president of North America for Thoratec, a developer of implantable mechanical circulatory support therapies. Previously, she held senior sales, marketing, business development and general management positions across a number of business units of Johnson and Johnson, including Acclarent and LifeScan.
“It is an exciting time to join ATI as we expand our commercial presence in Europe and accelerate our U.S. clinical trial. The published clinical results for the Pulsante Microstimulator are compelling and demonstrate that we truly can improve the quality of life for many patients by freeing them from the pain of disabling headaches,” said Pellegrini.
Company executives also appointed Gerhard Burbach, former CEO of Thoratec and currently an independent board member of ATI, as been board chairman.
“Niamh brings an impressive track record of driving growth in multinational medical device businesses where she has consistently built and maintained leading market positions,” said Burbach. "We are pleased to have such an accomplished executive join ATI at this important point in the company’s development, and we look forward to strong commercial and clinical success under her very capable leadership."
Autonomic Technologies Inc. develops and commercializes therapies to treat autonomic disorders, particularly severe headaches. The company’s initial product, the Pulsante Microstimulator, is CE marked in Europe for the treatment of cluster headache. The device (also known as ATI Neurostimulation System) is under an investigational device exemption study in the United States for the treatment of chronic cluster headache. ATI is backed by European and U.S. investors including Edmond de Rothschild Investment Partners, Forbion Capital Partners, HBM Healthcare Investments, Kleiner Perkins Caufield and Byers, InterWest Partners, Aberdare Ventures, Novartis Venture Funds, Capital Royalty Group and Cleveland Clinic. The company is headquartered in the San Francisco Bay, Calif., area, with offices in Germany and Switzerland.